Cardiac implantable electronic device infection in patients at risk

Arrhythmia and Electrophysiology Review

Volumn 5, Issue 1, 2016, Pages 65-71

  Tarakji, Khaldoun G ^a   Ellis, Christopher R ^b   Defaye, Pascal ^c   Kennergren, Charles ^d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antibacterial envelope; Cardiovascular implantable electronic device infections; Implantable cardioverter defibrillators; Pacemaker; Transvenous lead extraction

Indexed keywords

CEFAZOLIN; NEOMYCIN; VANCOMYCIN;

AGE DISTRIBUTION; ANTIMICROBIAL THERAPY; ARTICLE; ASPIRATION; BACTEREMIA; BLOOD CULTURE; CARDIAC RESYNCHRONIZATION THERAPY DEVICE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CARDIOVASCULAR THERAPEUTIC DEVICE; CLINICAL FEATURE; DEVICE INFECTION; DEVICE REMOVAL; ENDOCARDITIS; EQUIPMENT DESIGN; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; IMPLANTED HEART PACEMAKER; INFECTION CONTROL; INFECTION RISK; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; NONHUMAN; POPULATION RISK; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; RISK FACTOR; TREATMENT DURATION; VEIN THROMBOSIS;

EID: 85006287356     PISSN: 20503369     EISSN: 20503377     Source Type: Journal    
DOI: 10.15420/aer.2015.27.2     Document Type: Article

References (84)

1. Beck H, Boden WE, Patibandla S, et al. 50th anniversary of the first successful permanent pacemaker implantation in the United States: historical review and future directions. Am J Cardiol 2010;106:810-8. PMID: 21391322.
2. Uslan DZ, Tleyjeh IM, Baddour LM, et al. Temporal trends in permanent pacemaker implantation: a populationbased study. Am Heart J 2008;155:896-903. DOI: 10.1016/j. ahj.2007.12.022; PMID: 18440339; PMCID: PMC2597171.
3. Greenspon AJ, Patel JD, Lau E, et al. 16-year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008. J Am Coll Cardiol 2011;58:1001-6. DOI: 10.1016/j. jacc.2011.04.033; PMID: 21867833.
4. Mond HG, Proclemer A. The 11th world survey of cardiac pacing and implantable cardioverter-defibrillators: calendar year 2009 - a World Society of Arrhythmia's project, Pacing Clin Electrophysiol 2011;34:1013-27. DOI: 10.1111/j.1540 8159.2011.03150.x; PMID: 21707667.
5. Cabell CH, Heidenreich PA, Chu VH, et al. Increasing rates of cardiac device infections among Medicare beneficiaries: 1990-1999. Am Heart J 2004;147:582-6. PMID: 15077071.
6. Uslan DZ, Gleva MJ, Warren DK, et al. Cardiovascular implantable electronic device replacement infections and prevention: results from the REPLACE Registry. Pacing Clin Electrophysiol 2012;35:81-7. DOI: 10.1111/j.1540-8159.2011.03257.x; PMID: 22077194.
7. Klug D, Balde M, Pavin D, et al. Risk factors related to infections of implanted pacemakers and cardioverterdefibrillators: results of a large prospective study. Circulation 2007;116:1349-55. PMID: 17724263.
8. Poole JE, Gleva MJ, Mela T, et al. Complication rates associated with pacemaker or implantable cardioverterdefibrillator generator replacements and upgrade procedures: results from the REPLACE registry. Circulation 2010;122:1553-61. DOI: 10.1161/CIRCULATIONAHA.110.976076; PMID: 20921437.
9. Voigt A, Shalaby A, Saba S. Continued rise in rates of cardiovascular implantable electronic device infections in the United States: temporal trends and causative insights. Pacing Clin Electrophysiol 2010;33:414-9. DOI: 10.1111/j.1540-8159.2009.02569.x; PMID: 19793359.
10. Borleffs CJ, Thijssen J, de Bie MK, et al. Recurrent implantable cardioverter-defibrillator replacement is associated with an increasing risk of pocket-related complications. Pacing Clin Electrophysiol 2010;33:1013-9. DOI: 10.1111/j.1540-8159.2010.02780.x. PMID: 20456647.
11. Kurtz SM, Ochoa JA, Lau E, et al. Implantation trends and patient profiles for pacemakers and implantable cardioverter defibrillators in the United States: 1993-2006. Pacing Clin Electrophysiol 2010;33:705-11. DOI: 10.1111/j.1540-8159.2009.02670.x; PMID: 20059714.
12. Greenspon AJ, Patel JD, Lau E, et al. Trends in permanent pacemaker implantation in the United States from 1993 to 2009: increasing complexity of patients and procedures. J Am Coll Cardiol 2012;60:1540-5. DOI: 10.1016/j.jacc.2012.07.017; PMID: 22999727.
13. Centers for Medicare & Medicaid Services. U.S. Department of Health and Human Services Inpatient Prospective Payment System (IPPS) Final Rule FY2013. http://www. cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ AcuteInpatientPPS/index.html?redirect=/AcuteInpatientPPS/ IPPS2013/list.asp (accessed 14 January 2016).
14. Sohail MR, Henrikson CA, Braid-Forbes MJ, et al. Mortality and cost associated with cardiovascular implantable electronic device infections. Arch Intern Med 2011;171:1821-8. DOI: 10.1001/archinternmed.2011.441; PMID: 21911623.
15. Greenspon AJ, Patel JD, Lau E, et al. Inpatient vs. outpatient device implantation surgery: impact on cardiac implantable electronic device infection. Poster presented at the Heart Rhythm Society 34th Annual Scientific Session, Denver, CO, 8-11 May 2013. Po02-43.
16. Bloom H, Heeke B, Leon A, et al. Renal insufficiency and the risk of infection from pacemaker or defibrillator surgery. Pacing Clin Electrophysiol 2006;29:142-5. PMID: 16492298.
17. Lekkerkerker JC, van Nieuwkoop C, Trines SA, et al. Risk factors and time delay associated with cardiac device infections: Leiden device registry. Heart 2009;95:715-20. DOI: 10.1136/hrt.2008.151985; PMID: 19036758.
18. Herce B, Nazeyrollas P, Lesaffre F, et al. Risk factors for infection of implantable cardiac devices: data from a registry of 2496 patients. Europace 2013;15:66-70. DOI: 10.1093/ europace/eus284; PMID: 23097224.
19. Sohail MR, Uslan DZ, Khan AH, et al. Risk factor analysis of permanent pacemaker infection. Clin Infect Dis 2007;45:166-73. PMID: 17578774.
20. Howarth DM, Curteis PG, Gibson S. Infected cardiac pacemaker wires demonstrated by Tc-99m labeled white blood cell scintigraphy. Clin Nucl Med 1998;23:74-6. PMID: 9481492.
21. Romeyer-Bouchard C, Da Costa A, Dauphinot V, et al. Prevalence and risk factors related to infections of cardiac resynchronization therapy devices. Eur Heart J 2010;31:203-10.DOI: 10.1093/eurheartj/ehp421; PMID: 19875388.
22. Kleemann T, Becker T, Strauss M, et al. Prevalence of bacterial colonization of generator pockets in implantable cardioverter defibrillator patients without signs of infection undergoing generator replacement or lead revision. Europace 2010;12:58-63.DOI: 10.1093/europace/eup334; PMID: 19861383.
23. Mittal S, Shaw RE, Michel K, et al. Cardiac implantable electronic device infections: incidence, risk factors, and the effect of the AigisRx antibacterial envelope. Heart Rhythm 2014;11:595-601. DOI: 10.1016/j.hrthm.2013.12.013; PMID: 24333543.
24. Da Costa A, Lelievre H, Kirkorian G, et al. Role of the preaxillary flora in pacemaker infections: a prospective study. Circulation 1998;97:1791-5. PMID: 9603533.
25. Tarakji KG, Chan EJ, Cantillon DJ, et al. Cardiac implantable electronic device infections: presentation, management, and patient outcomes. Heart Rhythm 2010;7:1043-7. DOI: 10.1016/j. hrthm.2010.05.016; PMID: 20470904.
26. Sohail MR, Uslan DZ, Khan AH, et al. Management and outcome of permanent pacemaker and implantable cardioverter-defibrillator infections. J Am Coll Cardiol 2007;49:1851-9. PMID: 17481444.
27. Margey R, McCann H, Blake G, et al. Contemporary management of and outcomes from cardiac device related infections. Europace 2010;12:64-70. DOI: 10.1093/europace/ eup362; PMID: 1991031.
28. Baddour LM, Epstein AE, Erickson CC, et al. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation 2010;121:458-77. DOI: 10.1161/ CIRCULATIONAHA.109.192665; PMID: 20048212.
29. Greenspon AJ, Rhim ES, Mark G, et al. Lead-associated endocarditis: the important role of methicillin-resistant Staphylococcus aureus. Pacing Clin Electrophysiol 2008;31:548-53.DOI: 10.1111/j.1540-8159.2008.01039.x; PMID: 18439167.
30. Klug D, Lacroix D, Savoye C, et al. Systemic infection related to endocarditis on pacemaker leads: clinical presentation and management. Circulation 1997;95:2098-107. PMID: 9133520.
31. Klug D, Wallet F, Lacroix D, et al. Local symptoms at the site of pacemaker implantation indicate latent systemic infection. Heart 2004;90:882-6. PMID: 15253959.
32. Wazni O, Epstein LM, Carrillo RG, et al. Lead extraction in the contemporary setting: the LExICon study: an observational retrospective study of consecutive laser lead extractions. J Am Coll Cardiol 2010;55:579-86. DOI: 10.1016/j jacc.2009.08.070; PMID: 20152562.
33. Golzio PG, Fanelli AL, Vinci M, et al. Lead vegetations in patients with local and systemic cardiac device infections: prevalence, risk factors, and therapeutic effects. Europace 2013;15:89-100. DOI: 10.1093/europace/eus240; PMID: 22968846.
34. Kim DH, Tate J, Dresen WF, et al. Cardiac implanted electronic device-related infective endocarditis: clinical features, management, and outcomes of 80 consecutive patients. Pacing Clin Electrophysiol 2014;37:978-85. DOI: 10.1111/ pace.12452; PMID: 25060820.
35. Tarakji KG, Wilkoff BL. Management of cardiac implantable electronic device infections: the challenges of understanding the scope of the problem and its associated mortality. Expert Rev Cardiovasc Ther 2013;11:607-16. DOI: 10.1586/erc.12.190; PMID: 23621142.
36. Rundstrom H, Kennergren C, Andersson R, et al. Pacemaker endocarditis during 18 years in Göteborg. Scand J Infect Dis 2004;36:674-9. PMID: 15370655.
37. Madhavan M, Sohail MR, Friedman PA, et al. Outcomes in patients with cardiovascular implantable electronic devices and bacteremia caused by Gram-positive cocci other than Staphylococcus aureus. Circ Arrhythm Electrophysiol 2010;3:639-45. DOI: 10.1161/CIRCEP.110.957514; PMID: 20852296.
38. Sarrazin JF, Philippon F, Tessier M, et al. Usefulness of fluorine-18 positron emission tomography/computed tomography for identification of cardiovascular implantable electronic device infections. J Am Coll Cardiol 2012;59:1616-25.DOI: 10.1016/j.jacc.2011.11.059; PMID: 22538331.
39. Ahmed FZ, James J, Cunnington C, et al. Early diagnosis of cardiac implantable electronic device generator pocket infection using (1)(8)F-FDG-PET/CT. Eur Heart J Cardiovasc Imaging 2015;16:521-30. DOI: 10.1093/ehjci/jeu295. Epub 2015 Feb 3; PMID: 25651856. PMCID: PMC4407104.
40. Sohail MR, Sultan OW, Raza SS. Contemporary management of cardiovascular implantable electronic device infections. Expert Rev Anti Infect Ther 2010;8:831-9. DOI: 10.1586/eri.10.54; PMID: 20586567.
41. Wilkoff BL, Love CJ, Byrd CL, et al. Transvenous lead extraction: Heart Rhythm Society expert consensus on facilities, training, indications, and patient management. Heart Rhythm 2009;6:1085-104. DOI: 10.1016/j. hrthm.2009.05.020; PMID: 19560098.
42. Deharo JC, Bongiorni MG, Rozkovec A, et al. Pathways for training and accreditation for transvenous lead extraction: a European Heart Rhythm Association position paper. Europace 2012;14:124-34. DOI: 10.1093/europace/eur338; PMID: 22167387.
43. Chua JD, Wilkoff BL, Lee I, et al. Diagnosis and management of infections involving implantable electrophysiologic cardiac devices. Ann Intern Med 2000;133:604-8. PMID: 11033588.
44. del Río A, Anguera I, Miró JM, et al. Surgical treatment of pacemaker and defibrillator lead endocarditis: the impact of electrode lead extraction on outcome. Chest 2003;124:1451-9.PMID: 14555579.
45. Cacoub P, Leprince P, Nataf P, et al. Pacemaker infective endocarditis. Am J Cardiol 1998;82:480-4. PMID: 9723637.
46. Le KY, Sohail MR, Friedman PA, et al. Impact of timing of device removal on mortality in patients with cardiovascular implantable electronic device infections. Heart Rhythm 2011;8:1678-85. DOI: 10.1016/j.hrthm.2011.05.015; PMID: 21699855.
47. Voigt A, Shalaby A, Saba S. Rising rates of cardiac rhythm management device infections in the United States: 1996 through 2003. J Am Coll Cardiol 2006;48:590-1. PMID: 16875991.
48. Bongiorni MG. ELECTRa (European Lead Extraction ConTRolled Registry: preliminary data on Transvenous Lead Extraction in Europe, Presented at the ESC Congress, Barcelona, Spain, 30 August 2014.
49. Habib A, Le KY, Baddour LM, et al. Predictors of mortality in patients with cardiovascular implantable electronic device infections. Am J Cardiol 2013;111:874-9. DOI: 10.1016/j. amjcard.2012.11.052; PMID: 23276467.
50. Brunner MP, Cronin EM, Wazni O, et al. Outcomes of patients requiring emergent surgical or endovascular intervention for catastrophic complications during transvenous lead extraction. Heart Rhythm 2014;11:419-25. DOI: 10.1016/j. hrthm.2013.12.004; PMID: 24315967.
51. Brunner MP, Cronin EM, Duarte VE, et al. Clinical predictors of adverse patient outcomes in an experience of more than 5000 chronic endovascular pacemaker and defibrillator lead extractions. Heart Rhythm 2014;11:799-805. DOI: 10.1016/j. hrthm.2014.01.016; PMID: 24444444.
52. Brunner MP, Yu C, Hussein AA, et al. Nomogram for predicting 30-day all-cause mortality after transvenous pacemaker and defibrillator lead extraction. Heart Rhythm 2015;2:2381-6.DOI: 10.1016/j.hrthm.2015.07.024; PMID: 26190318.
53. Byrd CL, Wilkoff BL, Love CJ, et al. Clinical study of the laser sheath for lead extraction: the total experience in the United States. Pacing Clin Electrophysiol 2002;25:804-8. PMID: 12049372.
54. Wilkoff BL, Byrd CL, Love CJ, et al. Pacemaker lead extraction with the laser sheath: results of the pacing lead extraction with the excimer sheath (PLEXES) trial. J Am Coll Cardiol 1999;33:1671-6. PMID: 10334441.
55. Oto A, Aytemir K, Canpolat U, et al. Evolution in transvenous extraction of pacemaker and implantable cardioverter defibrillator leads using a mechanical dilator sheath. Pacing Clin Electrophysiol 2012;35:834-40. DOI: 10.1111/j.1540-8159.2012.03385.x; PMID: 22486778.
56. Kocabas U, Duygu H, Eren NK, et al. [Evaluation of lead extraction procedures using the Evolution Mechanical Dilatator Sheath lead extraction system: A single centre experience]. Turk Kardiyol Dern Ars 2015;43:350-5. DOI: 10.5543/tkda.2015.76329; PMID: 26142788.
57. Aksu T, Guray U, Sen T, et al. Use of the mechanical dilator sheath for removal of endocardial leads: a single center experience. Pacing Clin Electrophysiol 2012;35:514-8. DOI: 10.1111/j.1540-8159.2012.03329.x; PMID: 22353144.
58. Hussein AA, Wilkoff BL, Martin DO, et al. Initial experience with the Evolution mechanical dilator sheath for lead extraction: safety and efficacy. Heart Rhythm 2010;7:870-3. DOI: 10.1016/j.hrthm.2010.03.019; PMID: 20346418.
59. Kennergren C, Schaerf RH, Sellers TD, et al. Cardiac lead extraction with a novel locking stylet. J Interv Card Electrophysiol 2000;4:591-3. PMID: 11141204.
60. Maytin M, Jones SO, Epstein LM. Long-term mortality after transvenous lead extraction. Circ Arrhythm Electrophysiol 2012;5:252-7. DOI: 10.1161/CIRCEP.111.965277. PMID: 22362891.
61. Deckx S, Marynissen T, Rega F, et al. Predictors of 30-day and 1-year mortality after transvenous lead extraction: a singlecentre experience. Europace 2014;16:1218-25. DOI: 10.1093/ europace/eut410; PMID: 24569572.
62. Hamid S, Arujuna A, Ginks M, et al. Pacemaker and defibrillator lead extraction: predictors of mortality during follow-up. Pacing Clin Electrophysiol 2010;33:209-16. DOI: 10.1111/j.1540-8159.2009.02601.x; PMID: 19889182.
63. Tarakji KG, Wazni OM, Harb S, et al. Risk factors for 1-year mortality among patients with cardiac implantable electronic device infection undergoing transvenous lead extraction: the impact of the infection type and the presence of vegetation on survival. Europace 2014;16:1490-5. DOI: 10.1093/europace/ euu147; PMID: 25087154.
64. Novak M, Dvorak P, Kamaryt P, et al. Autopsy and clinical context in deceased patients with implanted pacemakers and defibrillators: intracardiac findings near their leads and electrodes. Europace 2009;11:1510-6. DOI: 10.1093/europace/ eup216; PMID: 19684037.
65. Reddy VY, Knops RE, Sperzel J, et al. Permanent leadless cardiac pacing: results of the LEADLESS trial. Circulation 2014;129:1466-71. DOI: 10.1161/ CIRCULATIONAHA.113.006987; PMID: 24664277.
66. Fudim M, Fredi JL, Ball SK, et al. Transcatheter leadless pacemaker implantation for complete heart block following CoreValve transcatheter aortic valve replacement. J Cardiovasc Electrophysiol 2016;27:125-6. DOI: 10.1111/ jce.12745; PMID: 26100053.
67. Steinwender C, Hönig S, Saleh, K, et al. First-in-man experience with a minimally invasive transcatheter pacemaker. Presented at Cardiostim 2014, Nice, France,19 June 2014. Abstract 83/1.
68. Gold MR. Are leadless pacemakers a niche or the future of device therapy? J Am Coll Cardiol 2015;65:1505-8. DOI: 10.1016/j.jacc.2015.02.021; PMID: 25881931.
69. Chang PM, Doshi R, Saxon LA. Subcutaneous implantable cardioverter-defibrillator. Circulation 2014;129:e644-6. DOI: 10.1161/CIRCULATIONAHA.113.006645; PMID: 24914020.
70. Darouiche RO, Wall MJ Jr, Itani KM, et al. Chlorhexidine-alcohol versus povidone-iodine for surgical-site antisepsis. N Engl J Med 2010;362:18-26. DOI: 10.1056/NEJMoa0810988; PMID: 20054046.
71. Qintar M, Zardkoohi O, Hammadah M, et al. The impact of changing antiseptic skin preparation agent used for cardiac implantable electronic device (CIED) procedures on the risk of infection. Pacing Clin Electrophysiol 2015;38:240-6. DOI: 10.1056/NEJMoa0810988; PMID: 20054046.
72. Da Costa A, Tulane C, Dauphinot V, et al. Preoperative skin antiseptics for prevention of cardiac implantable electronic device infections: a historical-controlled interventional trial comparing aqueous against alcoholic povidone-iodine solutions. Europace 2015;17:1092-8. DOI: 10.1093/europace/ euu293; PMID: 25917024.
73. Marsch G, Mashaqi B, Burgwitz K, et al. Prevention of pacemaker infections with perioperative antimicrobial treatment: an in vitro study. Europace 2014;16:604-11. DOI: 10.1093/europace/eut222; PMID: 23928734.
74. de Oliveira JC, Martinelli M, Nishioka SA, et al. Efficacy of antibiotic prophylaxis before the implantation of pacemakers and cardioverter-defibrillators: results of a large, prospective, randomized, double-blinded, placebo-controlled trial. Circ Arrhythm Electrophysiol 2009;2:29-34. DOI: 10.1161/ CIRCEP.108.795906; PMID: 19808441.
75. Khalighi K, Aung TT, Elmi F. The role of prophylaxis topical antibiotics in cardiac device implantation. Pacing Clin Electrophysiol 2014;37:304-11. DOI: 10.1111/pace.12280; PMID: 24164587.
76. Senaratne JM, Jayasuriya A, Irwin M, et al. A 19-year study on pacemaker-related infections: a claim for using postoperative antibiotics. Pacing Clin Electrophysiol 2014;37:947-54. DOI: 10.1111/pace.12403; PMID: 24766534.
77. Connolly SJ, Philippon F, Longtin Y, et al. Randomized cluster crossover trials for reliable, efficient, comparative effectiveness testing: design of the Prevention of Arrhythmia Device Infection Trial (PADIT). Can J Cardiol 2013;29:652-8.DOI: 10.1016/j.cjca.2013.01.020; PMID: 23702356.
78. Prevention of Arrhythmia Device Infection Trial (PADIT). https://clinicaltrials.gov/ct2/show/NCT01628666 Accessed 25 January 2016.
79. Bloom HL, Constantin L, Dan D, et al. Implantation success and infection in cardiovascular implantable electronic device procedures utilizing an antibacterial envelope. Pacing Clin Electrophysiol 2011;34:133-42. DOI: 10.1111/j.1540-8159.2010.02931.x; PMID: 20942819.
80. Kolek MJ, Dresen WF, Wells QS, Ellis CR. Use of an antibacterial envelope is associated with reduced cardiac implantable electronic device infections in high-risk patients. Pacing Clin Electrophysiol 2013;36:354-61. DOI: 10.1111/ pace.12063; PMID: 23252988.
81. Kolek MJ, Patel NJ, Clair WK, et al. Efficacy of a bioabsorbable antibacterial envelope to prevent cardiac implantable electronic device infections in high-risk subjects. J Cardiovasc Electrophysiol 2015;26:1111-6. DOI: 10.1111/jce.12768. Epub 2015 Sep 6; PMID: 26222980.
82. Henrickson CA, Sohail MR, Simons GR, et al. CITADEL/ CENTURION study interim analysis: use of an antibacterial envelope is associated with very low 90-day CIED infection rates. Presented at 34th Annual Scientific Sessions, Heart Rhythm 2013, Denver, Colorado, 11 May 2013. Abstract LB03-01.
83. Shariff N, Eby E, Adelstein E, et al. Health and economic outcomes associated with use of an antimicrobial envelope as a standard of care for cardiac implantable electronic device implantation. J Cardiovasc Electrophysiol 2015;26:783-9. DOI: 10.1111/jce.12684; PMID: 25845917.
84. Ellis CR, Kolek MJ. Rising infection rate in cardiac electronic device implantation; the role of the AIGISRx® antibacterial envelope in prophylaxis. Comb Prod Ther 2011;1:1-9.